TrialDiabetes, obesity & metabolism2019

Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial.

Kohei Kaku et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.